ProPhase Labs FY2024 EPS Estimate Reduced by Diamond Equity

ProPhase Labs, Inc. (NASDAQ:PRPH) – Stock analysts at Diamond Equity decreased their FY2024 earnings per share estimates for shares of ProPhase Labs in a research note issued to investors on Thursday, February 13th. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($1.27) for the year, down from their prior forecast of ($1.23). The consensus estimate for ProPhase Labs’ current full-year earnings is ($1.23) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.56) EPS.

Separately, StockNews.com started coverage on ProPhase Labs in a report on Sunday, February 9th. They issued a “sell” rating on the stock.

ProPhase Labs Stock Performance

ProPhase Labs stock opened at $0.33 on Monday. The stock’s 50-day moving average is $0.55 and its 200-day moving average is $1.53. The company has a market cap of $7.76 million, a price-to-earnings ratio of -0.26 and a beta of -0.37. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. ProPhase Labs has a 12 month low of $0.22 and a 12 month high of $7.48.

Institutional Investors Weigh In On ProPhase Labs

Hedge funds have recently modified their holdings of the stock. SVB Wealth LLC purchased a new stake in shares of ProPhase Labs during the 4th quarter valued at about $36,000. Warberg Asset Management LLC purchased a new stake in shares of ProPhase Labs during the 4th quarter valued at about $77,000. Perritt Capital Management Inc raised its holdings in shares of ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after buying an additional 107,068 shares during the period. Geode Capital Management LLC raised its holdings in shares of ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock valued at $154,000 after buying an additional 42,793 shares during the period. Finally, Sheets Smith Wealth Management purchased a new stake in shares of ProPhase Labs during the 4th quarter valued at about $158,000. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.